Soluble vascular endothelial growth factor receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis-independent manner.

abstract：:Replacement of the p53 tumor suppressor gene is a rational approach to the management of malignant gliomas because p53 is frequently mutated or inactivated in these cancers. Major weaknesses of this approach are that malignant gliomas are mixtures of cells with wild-type and mutant p53, and that tumor cells exhibiting...

journal_title：Human gene therapy

authors： Ito H,Kanzawa T,Miyoshi T,Hirohata S,Kyo S,Iwamaru A,Aoki H,Kondo Y,Kondo S

更新日期：2005-06-01 00:00:00

abstract：:Gene therapy for Duchenne muscular dystrophy will likely require that the corrective dystrophin gene be delivered to a high fraction of muscle fibers in vivo. Because of the large size of the dystrophin cDNA, adenoviral (Ad) vectors have been developed for this application. However, Ad vectors transduce mature muscle ...

journal_title：Human gene therapy

authors： Menezes KM,Mok HS,Barry MA

更新日期：2006-03-01 00:00:00

abstract：:The expanding use of adenoviral vectors for gene therapy has brought about the need for new analytical tools. We have developed an anion-exchange high-performance liquid chromatography method to analyze recombinant adenovirus serotype 5 samples. Before this assay, available analytical methods consisted of either long-...

journal_title：Human gene therapy

authors： Shabram PW,Giroux DD,Goudreau AM,Gregory RJ,Horn MT,Huyghe BG,Liu X,Nunnally MH,Sugarman BJ,Sutjipto S

更新日期：1997-03-01 00:00:00

abstract：:Duchenne muscular dystrophy (DMD) typically occurs as a result of truncating mutations in the DMD gene that result in a lack of expression of the dystrophin protein in muscle fibers. Various therapies under development are directed toward restoring dystrophin expression at the subsarcolemmal membrane, including gene t...

journal_title：Human gene therapy

authors： Flanigan KM,Campbell K,Viollet L,Wang W,Gomez AM,Walker CM,Mendell JR

更新日期：2013-09-01 00:00:00

abstract：:The epithelial-mesenchymal transition (EMT) has been recognized to occur during embryonic development, fibrosis, and tumor metastasis. Nuclear factor (NF)-κB plays a central role in mediating the inflammation and wound-healing responses during liver fibrogenesis. However, the involvement of NF-κB during EMT in liver c...

journal_title：Human gene therapy

authors： Kim KH,Lee WR,Kang YN,Chang YC,Park KK

更新日期：2014-08-01 00:00:00

abstract：:Adeno-associated virus (AAV) gene transfer is a promising treatment for genetic abnormalities. Optimal AAV vectors are showing success in clinical trials. Gene transfer to skeletal muscle and liver is being explored as a potential therapy for some conditions, that is, α1-antitrypsin (AAT) disorder and hemophilia B. Ex...

journal_title：Human gene therapy

authors： Carrig S,Bijjiga E,Wopat MJ,Martino AT

更新日期：2016-11-01 00:00:00

abstract：:To develop a potential gene therapy strategy for the treatment of hemophilia A, we constructed several retroviral vectors expressing a B-domain-deleted factor VIII (FVIII) cDNA. We confirmed previous reports that when the FVIII cDNA is inserted into a retroviral vector, the vector mRNA is decreased resulting in signif...

journal_title：Human gene therapy

authors： Chuah MK,VandenDriessche T,Morgan RA

更新日期：1995-11-01 00:00:00

abstract：:Activation of T cells is necessary for efficient retroviral-mediated gene transfer. In addition, if the population of infused cells is to be limited to transduced cells, a means of positive selection is required. We describe a clinical scale procedure for activation of donor T cells with anti-CD3/CD28 beads followed b...

journal_title：Human gene therapy

authors： Orchard PJ,Blazar BR,Burger S,Levine B,Basso L,Nelson DM,Gordon K,McIvor RS,Wagner JE,Miller JS

更新日期：2002-05-20 00:00:00

abstract：:Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronect...

journal_title：Human gene therapy

authors： Panetta CJ,Miyauchi K,Berry D,Simari RD,Holmes DR,Schwartz RS,Caplice NM

更新日期：2002-02-10 00:00:00

abstract：:Fibroblast-like synoviocytes (FLSs) participate in the pathogenesis of rheumatoid arthritis (RA). Emerging evidence has highlighted the role of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and its potential involvement in RA. In this study, we test the hypothesis that the MALAT1 ...

journal_title：Human gene therapy

authors： Li GQ,Fang YX,Liu Y,Meng FR,Wu X,Zhang CW,Zhang Y,Liu D,Gao B

更新日期：2019-08-01 00:00:00

abstract：:Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a "naked" DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the alpha, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patient...

journal_title：Human gene therapy

authors： Melman A,Bar-Chama N,McCullough A,Davies K,Christ G

更新日期：2006-12-01 00:00:00

abstract：:Newcastle disease virus (NDV) is a naturally oncolytic virus that has been shown to be safe and effective for cancer therapy. Tumor virotherapy using NDV emerged in the 1950s and has advanced more recently by the increased availability of reverse genetics technology. In this study, we constructed a reverse genetics sy...

journal_title：Human gene therapy

authors： Wei D,Sun N,Nan G,Wang Y,Liu HQ,Peeters B,Chen ZN,Bian H

更新日期：2012-07-01 00:00:00

abstract：:Gutted adenoviral (Ad) vectors have a greater cloning capacity and elicit less immune response than conventional Ad vectors. Unfortunately, clinical use of gutted vectors has been slowed by production difficulties, including low yield and a tendency for recombinant virus to emerge. These two problems are related, beca...

journal_title：Human gene therapy

authors： Hartigan-O'Connor D,Barjot C,Crawford R,Chamberlain JS

更新日期：2002-03-01 00:00:00

abstract：:Myelosuppression is the main side effect of cancer chemotherapy. An improved rate of retroviral vector-mediated gene transfer to hematopoietic stem cells, shown in more recent clinical trials, has created the basis to test the concept of myeloprotective gene therapy. We transplanted clinical-scale human peripheral blo...

journal_title：Human gene therapy

authors： Schiedlmeier B,Schilz AJ,Kühlcke K,Laufs S,Baum C,Zeller WJ,Eckert HG,Fruehauf S

更新日期：2002-01-20 00:00:00

abstract：:The central nervous system (CNS) is a predominant site of involvement in several lysosomal storage diseases (LSDs); and for many patients, these diseases are diagnosed only after the onset of symptoms related to the progressive accumulation of macromolecules within lysosomes. The mucopolysaccharidosis type VII (MPS VI...

journal_title：Human gene therapy

authors： Sferra TJ,Qu G,McNeely D,Rennard R,Clark KR,Lo WD,Johnson PR

更新日期：2000-03-01 00:00:00

abstract：:Human adenoviruses are the most widely used vectors in gene medicine, with applications ranging from oncolytic therapies to vaccinations, but adenovirus vectors are not without side effects. In addition, natural adenoviruses pose severe risks for immunocompromised people, yet infections are usually mild and self-limit...

journal_title：Human gene therapy

authors： Hendrickx R,Stichling N,Koelen J,Kuryk L,Lipiec A,Greber UF

更新日期：2014-04-01 00:00:00

abstract：:Transferring therapeutic genes into the nociceptive system, including dorsal root ganglia (DRGs) and the spinal cord, is potentially a powerful approach for the treatment of chronic pain in humans. Adeno-associated viral vectors (AAVs) are particularly useful in delivering foreign genes to targeted tissues because the...

journal_title：Human gene therapy

authors： Xu Y,Gu Y,Wu P,Li GW,Huang LY

更新日期：2003-06-10 00:00:00

abstract：:Less than 20% of the protein coding genome is thought to be targetable using small molecules. mRNA therapies are not limited in the same way since in theory, they can silence or edit any gene by encoding CRISPR nucleases, or alternatively, produce any missing protein. Yet not all mRNA therapies are equally likely to s...

journal_title：Human gene therapy

authors： Da Silva Sanchez A,Paunovska K,Cristian A,Dahlman JE

更新日期：2020-09-01 00:00:00

abstract：:Adenoviruses (Ads) have shown great utility as vectors for the delivery of genes to mammalian cells, partly because of their ability to infect a wide range of different cell types independent of the replicative state of the cell. However, Ads do not transduce mature muscle efficiently because of low levels of the natu...

journal_title：Human gene therapy

authors： Bramson JL,Grinshtein N,Meulenbroek RA,Lunde J,Kottachchi D,Lorimer IA,Jasmin BJ,Parks RJ

更新日期：2004-02-01 00:00:00

abstract：:First-generation adenoviral (Ad) and high-capacity adenoviral (HC-Ad) vectors are efficient delivery vehicles for transferring therapeutic transgenes in vivo into tissues/organs. The initial successes reported with adenoviral vectors in preclinical trials have been limited by immune-related adverse side effects. This ...

journal_title：Human gene therapy

authors： Puntel M,Curtin JF,Zirger JM,Muhammad AK,Xiong W,Liu C,Hu J,Kroeger KM,Czer P,Sciascia S,Mondkar S,Lowenstein PR,Castro MG

更新日期：2006-05-01 00:00:00

abstract：:Accurate quantification of gene transfer (or gene correction) is a universal challenge in the field of gene therapy. In developing a clinical trial of lymphocyte gene therapy for Hunter syndrome (mucopolysaccharidosis type II), methods using Southern blot or automated DNA sequencing technology were employed, but found...

journal_title：Human gene therapy

authors： Becker K,Pan D,Whitley CB

更新日期：1999-10-10 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, and even under optimal therapy these patients face a poor prognosis. Here we report a novel gene therapy-based strategy to battle this disease. We show that the majority of pancreatic tumors overexpress c-erb-B2, which therefor...

journal_title：Human gene therapy

authors： Liu X,Li J,Tian Y,Xu P,Chen X,Xie K,Qiu Z,Wang Y,Zhang D,Wolf F,Li C,Huang Q

更新日期：2010-02-01 00:00:00

abstract：:The use of gene-engineered T cells expressing chimeric single-chain (scFv) receptors capable of codelivering CD28 costimulation and T cell receptor zeta chain (TCR-zeta) activation signals has emerged as a promising treatment regimen for cancer. Using retroviral transduction, primary human T lymphocytes were gene-engi...

journal_title：Human gene therapy

authors： Teng MW,Kershaw MH,Moeller M,Smyth MJ,Darcy PK

更新日期：2004-07-01 00:00:00

abstract：:Human hematopoietic stem cells (HSCs) are poorly transduced by vectors based on adenovirus serotype 5 (Ad5). This is primarily due to the paucity of the coxsackievirus-Ad receptor on these cells. In an attempt to change the tropism of Ad5, we constructed a series of chimeric E1-deleted Ad5 vectors in which the shaft a...

journal_title：Human gene therapy

authors： Knaän-Shanzer S,Van Der Velde I,Havenga MJ,Lemckert AA,De Vries AA,Valerio D

更新日期：2001-11-01 00:00:00

abstract：:This Phase I study, "Ribozyme Gene Therapy of HIV-1 Infection" (UCSD HSC #971072, FDA BB-IND 6405), is a prospective, open-label trial of infusion of autologous gene-altered cells into asymptomatic HIV-1 seropositive individuals. The objectives of this trial are to test the safety, feasibility, and potential efficacy ...

journal_title：Human gene therapy

authors： Wong-Staal F,Poeschla EM,Looney DJ

更新日期：1998-11-01 00:00:00

abstract：:Mucopolysaccharidosis type II (MPS II) is a neuropathic lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans (GAGs). We demonstrated that biochemical alterations in the brains of MPS II mice are not corrected by bone marrow transplantat...

journal_title：Human gene therapy

authors： Wakabayashi T,Shimada Y,Akiyama K,Higuchi T,Fukuda T,Kobayashi H,Eto Y,Ida H,Ohashi T

更新日期：2015-06-01 00:00:00

abstract：:Point mutations in the dystrophin gene cause dystrophin deficiency and muscular dystrophy in the mdx mouse and a subset of patients with Duchenne muscular dystrophy. As an approach to gene therapy for muscular dystrophies due to point mutations, we have studied the ability of RNA-DNA chimeric oligonucleotides (chimera...

journal_title：Human gene therapy

authors： Bertoni C,Rando TA

更新日期：2002-04-10 00:00:00

abstract：:Cell-based therapy for muscular dystrophies was initiated in humans after promising results obtained in murine models. Early trials failed to show substantial clinical benefit, sending researchers back to the bench, which led to the discovery of many hurdles as well as many new venues to optimize this therapeutic stra...

journal_title：Human gene therapy

authors： Negroni E,Bigot A,Butler-Browne GS,Trollet C,Mouly V

更新日期：2016-02-01 00:00:00

abstract：:We report a novel method for targeting adenovirus-mediated gene delivery. By irradiating mammalian cells prior to adenoviral transduction, adenoviral gene transfer is greatly improved and the adenoviral genome integrates into cellular DNA. In this work, human and rodent cell lines were irradiated and subsequently tran...

journal_title：Human gene therapy

authors： Zeng M,Cerniglia GJ,Eck SL,Stevens CW

更新日期：1997-06-10 00:00:00

abstract：:Cell therapies are treatments in which stem or progenitor cells are stimulated to differentiate into specialized cells able to home to and repair damaged tissues. After their discovery, endothelial progenitor cells (EPCs) stimulated worldwide interest as possible vehicles to perform autologous cell therapy of tumors. ...

journal_title：Human gene therapy

authors： Laurenzana A,Margheri F,Chillà A,Biagioni A,Margheri G,Calorini L,Fibbi G,Del Rosso M

更新日期：2016-10-01 00:00:00